Welcome to our dedicated page for Cybin SEC filings (Ticker: CYBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cybin Inc. filings document the U.S. disclosure record for its Helus Pharma clinical-stage pharmaceutical business. Form 6-K reports furnished by the Canadian issuer attach company news releases and, when specified, incorporate exhibits by reference into Form F-10 shelf registration materials.
The filings cover the company’s novel serotonergic agonist pipeline, including HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder, as well as clinical-research collaborations, regulatory-policy statements, scientific advisory board changes, management appointments, chief executive transition disclosures, listing and operating-name updates, and capital-structure matters related to shelf and equity distribution activity.
Cybin Inc. (CYBN) received a Schedule 13G showing that Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively report beneficial ownership of 3,072,250 common shares, representing 6.09% of the class as of the reported date.
The filing lists shared voting and dispositive power over 3,072,250 shares and no sole voting or dispositive power. The ownership calculation references 50,431,381 shares, derived from 49,894,131 shares outstanding as of October 28, 2025 plus 537,250 warrants that are exercisable subject to a 9.99% Maximum Percentage beneficial ownership cap. The certification states the securities were not acquired to change or influence control.
Cybin Inc. received an amended Schedule 13G filing reporting that Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively beneficially own 1,000,000 common shares, equal to 3.97% of the class. The Date of Event Which Requires Filing is 09/30/2025.
The reporting persons have shared voting and dispositive power over 1,000,000 shares and no sole voting or dispositive power. The filing indicates ownership of 5 percent or less of the class and includes a certification that the securities were not acquired to change or influence control of the issuer.
For context, the percent ownership is based on 25,188,217 common shares outstanding as of September 16, 2025, as cited from the issuer’s F-10. Information is stated as of October 29, 2025.
Cybin Inc. furnished a Form 6-K as a foreign private issuer, incorporating several exhibits by reference into its Form F-10 registration statement. The exhibits include a form of securities purchase agreement, forms of pre-funded warrant and warrant, a placement agency agreement dated October 27, 2025, and a legal consent from Aird & Berlis LLP. This connects key financing and warrant documents directly to the company’s existing Canadian short form base shelf registration on Form F-10.
Cybin Inc. (CYBN) filed a new Form D for an exempt offering under Rule 506(b). The notice covers stock options exercisable at CAD$8.39 per share, vesting in eight quarterly tranches beginning December 31, 2025.
Total amount sold is $0 USD, with $601,865 USD remaining to be sold. The company notes the total represents the maximum potential proceeds from option exercises. The filing lists a Date of First Sale: October 1, 2025, and reports $0 in finders’ fees. The issuer is incorporated in Ontario, Canada and identifies its industry as health care/biotechnology.
CYBIN INC. filed a Form D for a new, Regulation D exempt offering under Rule 506(b) to register up to $120,070 USD in potential proceeds, which represents the maximum amount potentially received from the exercise of stock options. No proceeds have been sold yet and total remaining to be sold is $120,070 USD. The securities consist primarily of stock options exercisable at CAD$11.00 per share that vest in eight quarterly tranches beginning September 30, 2025. The offering is intended to last more than one year. No sales commissions or finders’ fees were disclosed and no proceeds are allocated to named executives or directors. One investor is reported and one non-accredited investor has participated.
CYBIN INC. filed a Form D for a new, Regulation D exempt offering under Rule 506(b) to register up to $120,070 USD in potential proceeds, which represents the maximum amount potentially received from the exercise of stock options. No proceeds have been sold yet and total remaining to be sold is $120,070 USD. The securities consist primarily of stock options exercisable at CAD$11.00 per share that vest in eight quarterly tranches beginning September 30, 2025. The offering is intended to last more than one year. No sales commissions or finders’ fees were disclosed and no proceeds are allocated to named executives or directors. One investor is reported and one non-accredited investor has participated.